2
|
Jaraj D, Ahlgren J, Arnesson LG, Einbeigi Z, Höijer J, Klintman M, Malmström P, Vikhe Patil E, Sund M, Fredriksson I, Bergh J, Pettersson A. Abstract P2-08-05: Withdrawn. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p2-08-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
This abstract was withdrawn by the authors.
Citation Format: Jaraj D, Ahlgren J, Arnesson L-G, Einbeigi Z, Höijer J, Klintman M, Malmström P, Vikhe Patil E, Sund M, Fredriksson I, Bergh J, Pettersson A. Withdrawn [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P2-08-05.
Collapse
Affiliation(s)
- D Jaraj
- Clinical Epidemiology Unit, Karolinska Institutet, Stockholm, Sweden; Faculty of Medicine and Health, Örebro University, Örebro, Sweden; Linkoping University Hospital, Linköping, Sweden; Sahlgrenska University Hospital, Gothenburg, Sweden; Unit of Biostatistics, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; Faculty of Medicine, Skåne University Hospital, Lund University, Lund, Sweden; Umeå University, Umeå, Sweden; Karolinska Institute, Stockholm, Sweden; Karolinska Institutet, Breast Cancer Group and Radiumhemmet, Cancer Theme, Karolinska University Hospital, Stockholm, Sweden
| | - J Ahlgren
- Clinical Epidemiology Unit, Karolinska Institutet, Stockholm, Sweden; Faculty of Medicine and Health, Örebro University, Örebro, Sweden; Linkoping University Hospital, Linköping, Sweden; Sahlgrenska University Hospital, Gothenburg, Sweden; Unit of Biostatistics, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; Faculty of Medicine, Skåne University Hospital, Lund University, Lund, Sweden; Umeå University, Umeå, Sweden; Karolinska Institute, Stockholm, Sweden; Karolinska Institutet, Breast Cancer Group and Radiumhemmet, Cancer Theme, Karolinska University Hospital, Stockholm, Sweden
| | - L-G Arnesson
- Clinical Epidemiology Unit, Karolinska Institutet, Stockholm, Sweden; Faculty of Medicine and Health, Örebro University, Örebro, Sweden; Linkoping University Hospital, Linköping, Sweden; Sahlgrenska University Hospital, Gothenburg, Sweden; Unit of Biostatistics, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; Faculty of Medicine, Skåne University Hospital, Lund University, Lund, Sweden; Umeå University, Umeå, Sweden; Karolinska Institute, Stockholm, Sweden; Karolinska Institutet, Breast Cancer Group and Radiumhemmet, Cancer Theme, Karolinska University Hospital, Stockholm, Sweden
| | - Z Einbeigi
- Clinical Epidemiology Unit, Karolinska Institutet, Stockholm, Sweden; Faculty of Medicine and Health, Örebro University, Örebro, Sweden; Linkoping University Hospital, Linköping, Sweden; Sahlgrenska University Hospital, Gothenburg, Sweden; Unit of Biostatistics, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; Faculty of Medicine, Skåne University Hospital, Lund University, Lund, Sweden; Umeå University, Umeå, Sweden; Karolinska Institute, Stockholm, Sweden; Karolinska Institutet, Breast Cancer Group and Radiumhemmet, Cancer Theme, Karolinska University Hospital, Stockholm, Sweden
| | - J Höijer
- Clinical Epidemiology Unit, Karolinska Institutet, Stockholm, Sweden; Faculty of Medicine and Health, Örebro University, Örebro, Sweden; Linkoping University Hospital, Linköping, Sweden; Sahlgrenska University Hospital, Gothenburg, Sweden; Unit of Biostatistics, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; Faculty of Medicine, Skåne University Hospital, Lund University, Lund, Sweden; Umeå University, Umeå, Sweden; Karolinska Institute, Stockholm, Sweden; Karolinska Institutet, Breast Cancer Group and Radiumhemmet, Cancer Theme, Karolinska University Hospital, Stockholm, Sweden
| | - M Klintman
- Clinical Epidemiology Unit, Karolinska Institutet, Stockholm, Sweden; Faculty of Medicine and Health, Örebro University, Örebro, Sweden; Linkoping University Hospital, Linköping, Sweden; Sahlgrenska University Hospital, Gothenburg, Sweden; Unit of Biostatistics, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; Faculty of Medicine, Skåne University Hospital, Lund University, Lund, Sweden; Umeå University, Umeå, Sweden; Karolinska Institute, Stockholm, Sweden; Karolinska Institutet, Breast Cancer Group and Radiumhemmet, Cancer Theme, Karolinska University Hospital, Stockholm, Sweden
| | - P Malmström
- Clinical Epidemiology Unit, Karolinska Institutet, Stockholm, Sweden; Faculty of Medicine and Health, Örebro University, Örebro, Sweden; Linkoping University Hospital, Linköping, Sweden; Sahlgrenska University Hospital, Gothenburg, Sweden; Unit of Biostatistics, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; Faculty of Medicine, Skåne University Hospital, Lund University, Lund, Sweden; Umeå University, Umeå, Sweden; Karolinska Institute, Stockholm, Sweden; Karolinska Institutet, Breast Cancer Group and Radiumhemmet, Cancer Theme, Karolinska University Hospital, Stockholm, Sweden
| | - E Vikhe Patil
- Clinical Epidemiology Unit, Karolinska Institutet, Stockholm, Sweden; Faculty of Medicine and Health, Örebro University, Örebro, Sweden; Linkoping University Hospital, Linköping, Sweden; Sahlgrenska University Hospital, Gothenburg, Sweden; Unit of Biostatistics, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; Faculty of Medicine, Skåne University Hospital, Lund University, Lund, Sweden; Umeå University, Umeå, Sweden; Karolinska Institute, Stockholm, Sweden; Karolinska Institutet, Breast Cancer Group and Radiumhemmet, Cancer Theme, Karolinska University Hospital, Stockholm, Sweden
| | - M Sund
- Clinical Epidemiology Unit, Karolinska Institutet, Stockholm, Sweden; Faculty of Medicine and Health, Örebro University, Örebro, Sweden; Linkoping University Hospital, Linköping, Sweden; Sahlgrenska University Hospital, Gothenburg, Sweden; Unit of Biostatistics, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; Faculty of Medicine, Skåne University Hospital, Lund University, Lund, Sweden; Umeå University, Umeå, Sweden; Karolinska Institute, Stockholm, Sweden; Karolinska Institutet, Breast Cancer Group and Radiumhemmet, Cancer Theme, Karolinska University Hospital, Stockholm, Sweden
| | - I Fredriksson
- Clinical Epidemiology Unit, Karolinska Institutet, Stockholm, Sweden; Faculty of Medicine and Health, Örebro University, Örebro, Sweden; Linkoping University Hospital, Linköping, Sweden; Sahlgrenska University Hospital, Gothenburg, Sweden; Unit of Biostatistics, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; Faculty of Medicine, Skåne University Hospital, Lund University, Lund, Sweden; Umeå University, Umeå, Sweden; Karolinska Institute, Stockholm, Sweden; Karolinska Institutet, Breast Cancer Group and Radiumhemmet, Cancer Theme, Karolinska University Hospital, Stockholm, Sweden
| | - J Bergh
- Clinical Epidemiology Unit, Karolinska Institutet, Stockholm, Sweden; Faculty of Medicine and Health, Örebro University, Örebro, Sweden; Linkoping University Hospital, Linköping, Sweden; Sahlgrenska University Hospital, Gothenburg, Sweden; Unit of Biostatistics, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; Faculty of Medicine, Skåne University Hospital, Lund University, Lund, Sweden; Umeå University, Umeå, Sweden; Karolinska Institute, Stockholm, Sweden; Karolinska Institutet, Breast Cancer Group and Radiumhemmet, Cancer Theme, Karolinska University Hospital, Stockholm, Sweden
| | - A Pettersson
- Clinical Epidemiology Unit, Karolinska Institutet, Stockholm, Sweden; Faculty of Medicine and Health, Örebro University, Örebro, Sweden; Linkoping University Hospital, Linköping, Sweden; Sahlgrenska University Hospital, Gothenburg, Sweden; Unit of Biostatistics, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; Faculty of Medicine, Skåne University Hospital, Lund University, Lund, Sweden; Umeå University, Umeå, Sweden; Karolinska Institute, Stockholm, Sweden; Karolinska Institutet, Breast Cancer Group and Radiumhemmet, Cancer Theme, Karolinska University Hospital, Stockholm, Sweden
| |
Collapse
|
3
|
Wahlgren N, Thorén M, Höjeberg B, Käll TB, Laska AC, Sjöstrand C, Höijer J, Almqvist H, Holmin S, Lilja A, Fredriksson L, Lawrence D, Eriksson U, Ahmed N. Randomized assessment of imatinib in patients with acute ischaemic stroke treated with intravenous thrombolysis. J Intern Med 2017; 281:273-283. [PMID: 27862464 PMCID: PMC5573589 DOI: 10.1111/joim.12576] [Citation(s) in RCA: 37] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
BACKGROUND Imatinib, a tyrosine kinase inhibitor, has been shown to restore blood-brain barrier integrity and reduce infarct size, haemorrhagic transformation and cerebral oedema in stroke models treated with tissue plasminogen activator. We evaluated the safety of imatinib, based on clinical and neuroradiological data, and its potential influence on neurological and functional outcomes. METHODS A phase II randomized trial was performed in patients with acute ischaemic stroke treated with intravenous thrombolysis. A total of 60 patients were randomly assigned to four groups [3 (active): 1 (control)]; the active treatment groups received oral imatinib for 6 days at three dose levels (400, 600 and 800 mg). Primary outcome was any adverse event; secondary outcomes were haemorrhagic transformation, cerebral oedema, neurological severity on the National Institutes of Health Stroke Scale (NIHSS) at 7 days and at 3 months and functional outcomes on the modified Rankin scale (mRS). RESULTS Four serious adverse events were reported, which resulted in three deaths (one in the control group and two in the 400-mg dose group; one patient in the latter group did not receive active treatment and the other received two doses). Nonserious adverse events were mostly mild, resulting in full recovery. Imatinib ameliorated neurological outcomes with an improvement of 0.6 NIHSS points per 100 mg imatinib (P = 0.02). For the 800-mg group, the mean unadjusted and adjusted NIHSS improvements were 4 (P = 0.037) and 5 points (P = 0.012), respectively, versus controls. Functional independence (mRS 0-2) increased by 18% versus controls (61 vs. 79; P = 0.296). CONCLUSION This phase II study showed that imatinib is safe and tolerable and may reduce neurological disability in patients treated with intravenous thrombolysis after ischaemic stroke. A confirmatory randomized trial is currently underway.
Collapse
Affiliation(s)
- N Wahlgren
- Department of Neurology, Karolinska University Hospital, Stockholm, Sweden.,Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
| | - M Thorén
- Department of Neurology, Karolinska University Hospital, Stockholm, Sweden.,Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
| | - B Höjeberg
- Department of Neurology, Capio St Göran Hospital, Stockholm, Sweden
| | - T-B Käll
- Department of Internal Medicine, Södersjukhuset, Stockholm, Sweden
| | - A-C Laska
- Department of Internal Medicine, Danderyd Hospital, Stockholm, Sweden
| | - C Sjöstrand
- Department of Neurology, Karolinska University Hospital, Stockholm, Sweden.,Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
| | - J Höijer
- Unit of Biostatistics, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
| | - H Almqvist
- Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.,Department of Neuroradiology, Karolinska University Hospital, Stockholm, Sweden
| | - S Holmin
- Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.,Department of Neuroradiology, Karolinska University Hospital, Stockholm, Sweden
| | - A Lilja
- Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.,Department of Neuroradiology, Karolinska University Hospital, Stockholm, Sweden
| | - L Fredriksson
- Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden
| | - D Lawrence
- Department of Internal Medicine, Division of Cardiovascular Medicine, University of Michigan Medical School, Ann Arbor, MI, USA
| | - U Eriksson
- Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden
| | - N Ahmed
- Department of Neurology, Karolinska University Hospital, Stockholm, Sweden.,Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
| |
Collapse
|
4
|
Missailidis C, Höijer J, Johansson M, Ekström L, Bratt G, Hejdeman B, Bergman P. Vitamin D status in Well-Controlled Caucasian HIV Patients in Relation to Inflammatory and Metabolic Markers--A Cross-Sectional Cohort Study in Sweden. Scand J Immunol 2015; 82:55-62. [PMID: 25833795 PMCID: PMC4691317 DOI: 10.1111/sji.12299] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2015] [Accepted: 03/18/2015] [Indexed: 02/06/2023]
Abstract
To study vitamin D (25OH D3) in relation to (i) microbial translocation (ii) systemic inflammation and (iii) blood lipid markers, in Caucasian, well-controlled HIV patients and healthy controls, plasma and serum samples from n = 97 male, HIV patients on HAART with immeasurable viral load (<20 copies/ml) since median 6.5 years and no concurrent inflammatory or infectious disease and n = 30 healthy controls were analysed for (i) LPS; (ii) sCD14, hsCRP, IL-4, IL-6, IL-10, IL-17, MCP-1 and IFN-γ; as well as (iii) blood lipids. Vitamin D levels were similarly distributed and equally low in both HIV patients and controls. There was no association between vitamin D levels and markers of microbial translocation, systemic inflammation or dyslipidemia. LPS levels were similar in both groups but HIV patients expressed higher levels of sCD14 and hsCRP, with HIV as an independent risk factor. HIV patients had higher cholesterol and Apo B levels. Notably, more HIV patients smoked and smoking was associated with lower vitamin D levels. In conclusion; these well-treated Caucasian HIV patients had similar vitamin D levels as healthy controls. However, despite perfect virological control, they exhibited slightly increased inflammatory markers and disturbed blood lipids. However, neither of these parameters were associated with low vitamin D levels but appeared to be linked to the HIV-disease per se. Thus, the rationale for vitamin D substitution as a way to improve microbial translocation and systemic inflammation is not fully supported in this HIV population.
Collapse
Affiliation(s)
- C Missailidis
- Department of Laboratory Medicine (LABMED), Division of Clinical Microbiology, Karolinska Institute, Stockholm, Sweden.,Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden
| | - J Höijer
- Department of Environmental Medicine, Unit of Biostatistics, Karolinska Institute, Stockholm, Sweden
| | - M Johansson
- Department of Laboratory Medicine (LABMED), Division of Clinical Pharmacology, Karolinska Institute, Stockholm, Sweden
| | - L Ekström
- Department of Laboratory Medicine (LABMED), Division of Clinical Pharmacology, Karolinska Institute, Stockholm, Sweden
| | - G Bratt
- Department of Infectious Diseases, Venhälsan, South General Hospital, Stockholm, Sweden
| | - B Hejdeman
- Department of Infectious Diseases, Venhälsan, South General Hospital, Stockholm, Sweden
| | - P Bergman
- Department of Laboratory Medicine (LABMED), Division of Clinical Microbiology, Karolinska Institute, Stockholm, Sweden.,Department of Medicine, Center for Infectious Medicine (CIM), Karolinska Institute, Stockholm, Sweden
| |
Collapse
|